Regenerative Medicine: Tremendous Potential but Not Quite Ready for Prime-Time

Abstract

This guest editorial gives an overview of the field of regenerative medicine and the special issue.

Keywords

ethics regenerative medicine orthopedics musculoskeletal disease stem cells

Get full access to this article

View all access options for this article.

References

Sawamoto

Doi

Nakanishi

, et al. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease. Nature. 2025;641(8064):971-977. doi:10.1038/s41586-025-08700-0

Singh

Irfan

Fatima

Nazir

Verma

Akilimali

. Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease. Ann Med Surg. 2024;86(8):4555-4559. doi:10.1097/MS9.0000000000002146

Florida Senate Committee on Health Policy. CS/CS/SB 1768—stem cell therapy. 2025. Accessed July 23, 2025. https://www.flsenate.gov/PublishedContent/Session/2025/BillSummary/Health_HP1768hp_01768.pdf

Makary

Prasad

. Priorities for a new FDA. JAMA. 2025;2025:e10116. doi:10.1001/jama.2025.10116

U.S. Food and Drug Administration. Cell and gene therapy roundtable. June 5, 2025. Accessed July 23, 2025. https://www.fda.gov/vaccines-blood-biologics/workshops-meetings-conferences-biologics/cell-and-gene-therapy-roundtable-06052025

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB